Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Fosaprepitant (Primary) ; Dexamethasone; Olanzapine; Ondansetron; Ondansetron; Palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 30 Apr 2019 Planned End Date changed from 1 Mar 2020 to 1 Aug 2023.
- 30 Apr 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2023.
- 08 Nov 2018 Status changed from not yet recruiting to recruiting.